文献速递慢阻肺

pMDI与射流雾化器在COPD急性加重NIV中支气管扩张剂递送的随机药代动力学试验

Bronchodilator Drug Delivery With Pressurized Meter-Dose-Inhaler Versus Jet Nebulizer With Noninvasive-Ventilation in Acute-Exacerbation of COPD: A Randomized Controlled Pharmacokinetic Endpoint Trial.
PubMed 文献 · Respirology · 2026-10-21

本研究为随机开放标签试验,纳入需NIV的高碳酸血症性AECOPD成人患者,比较经改良NIV面罩的pMDI与吸气支路射流雾化器递送异丙托溴铵。30分钟血清异丙托溴铵几何均值pMDI组110.9 pg/mL高于雾化组51.6 pg/mL,GMR 2.15,贝叶斯分析显示GMR超过非劣效阈值0.80的概率为95.9%。结论认为pMDI经定制接口在NIV期间递送支气管扩张剂可行、安全、经济,且全身药物水平更高。

要点

  • pMDI经改良NIV面罩递送异丙托溴铵30分钟血清水平高于射流雾化(GMR 2.15)。
  • 6小时差异仍 favoring pMDI(GMR 3.18,p=0.022)。
  • 生理指标、血气及NIV时长组间相似,pMDI组ICU停留更短。

核心结论

  • pMDI经定制接口在NIV期间递送支气管扩张剂可行、安全、经济,且全身药物水平高于射流雾化。

研究设计与样本

  • 随机、开放标签试验,纳入需NIV的高碳酸血症性AECOPD成人患者,1:1随机分组。

主要发现

  • 30分钟血清异丙托溴铵几何均值pMDI组110.9 pg/mL,雾化组51.6 pg/mL,GMR 2.15。
  • 贝叶斯分析显示GMR超过非劣效阈值0.80的概率为95.9%。
  • 6小时差异仍 favoring pMDI(GMR 3.18;p=0.022;后验概率99.8%)。
  • 生理结局、气体交换及NIV时长组间相似,pMDI组ICU停留更短。
  • 未观察到安全性问题或器械相关并发症,事后成本分析显示pMDI治疗成本明显更低。

临床怎么用

  • 在需NIV的AECOPD患者中,可考虑使用经定制接口的pMDI递送支气管扩张剂替代射流雾化。

局限性

  • 样本量小,需更大规模多中心试验确定临床影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Non-invasive ventilation (NIV) and inhaled bronchodilator therapy are foundational in the management of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). However, optimal drug-delivery strategies during NIV remain uncertain. This study compared bronchodilator delivery via a pressurized metered-dose inhaler (pMDI) interface versus standard jet nebulization during NIV. METHODS: This randomized, open-label trial enrolled adults with hypercapnic AECOPD requiring NIV. Participants were randomized 1:1 to receive ipratropium bromide via pMDI using a modified NIV mask, or via jet nebulizer integrated into the inspiratory limb. Serum ipratropium concentrations at 30 min constituted the primary bioequivalence endpoint, analysed using geometric mean ratios (GMR) and Bayesian posterior probabilities. Secondary outcomes included changes in physiologic parameters, blood gases, ventilatory asynchrony, duration of stay and cost effectiveness. RESULTS: Forty-four patients were randomized; 41 were included in the intention-to-treat analysis (pMDI n = 20, nebulizer n = 21). At 30 min, geometric mean serum ipratropium levels were higher with pMDI (110.9 pg/mL) versus nebulization (51.6 pg/mL), yielding a GMR of 2.15. Bayesian analysis showed a 95.9% probability that GMR exceeded the non-inferiority threshold (0.80). At 6 h, differences again favoured pMDI (GMR 3.18; p = 0.022; posterior probability 99.8%). Physiologic outcomes, gas exchange, and NIV duration were similar between groups, though ICU stay was shorter in the pMDI arm. No safety concerns or device-related complications were observed. Post hoc cost analysis showed markedly lower therapy cost with pMDI. CONCLUSIONS: pMDI-based bronchodilator delivery during NIV using a customized interface is feasible, safe, cost-efficient, and achieves higher systemic drug levels than jet nebulization. Larger multicentre trials are warranted to determine clinical impact. TRIAL REGISTRATION: Clinical Trials Registry of India CTRI/2023/07/054734.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Raj V, Singh PK, Akondy R, et al. Bronchodilator Drug Delivery With Pressurized Meter-Dose-Inhaler Versus Jet Nebulizer With Noninvasive-Ventilation in Acute-Exacerbation of COPD: A Randomized Controlled Pharmacokinetic Endpoint Trial. Respirology. 2026. PMID: 42908195. doi:10.1002/resp.70334

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。